Asthma Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Asthma Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Asthma Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Asthma Market by downloading the comprehensive report from DelveInsight @ Asthma Market
Key Takeaways from the Asthma Market Report
- In September 2024:- AstraZeneca- A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma. The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma.
- In September 2024:- Chiesi Farmaceutici S.p.A.- The purpose of this study is to evaluate the efficacy and safety of CHF6001 (Tanimilast) as add-on to maintenance of inhaled corticosteroids in combination with Long-acting ß2-agonists in the target patient population. (TANGO)
- As per DelveInsight analysis, there were approximately 55 million diagnosed prevalent cases of asthma, in the 7MM, in 2023. These cases are projected to increase during the forecast period (2024-2034).
- Among the 7MM, the US accounted for the highest, approximately 47% of the total diagnosed prevalent cases in 2023, while Spain accounted for the least with nearly 5% of the total.
- According to DelveInsight analysis, there were around 4.8 million pediatrics and 21.2 million adults cases of asthma in the US in 2023, with numbers expected to rise by 2034.
- The leading Asthma Companies such as Cipla Ltd, Hamad Medical Corporation, Areteia Therapeutics, AstraZeneca, Amgen, GSK, Sanofi, TEVA Pharmaceutical, Regeneron Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, and others.
- Promising Asthma Therapies such as Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, Tezepelumab, GSK3511294 (Depemokimab), and others.
Gain a competitive edge in the Asthma Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Asthma Treatment Drugs
Asthma Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Cases
- Age-specific Cases
- Gender-specific Cases
- Severity-specific Cases
- Type-specific Severity Cases
Asthma Treatment Market
The mainstay treatment for persistent asthma consists of inhaled corticosteroids. Quick-relief (reliever) or rescue medicines quickly ease symptoms that arise acutely. Short-acting beta-agonists (SABAs) rapidly reduce airway bronchoconstriction and are recommended rescue medication for rapid symptom relief. Additional long-term controller medicines, such as long-acting beta 2 agonists (LABA), montelukast, or theophylline, are added if asthma is still uncontrolled.
Discover key developments and opportunities in the Asthma Market. Click here to learn more from DelveInsight’s latest report @ Asthma Market Size
Asthma Marketed Drugs
- TEZSPIRE (tezepelumab-ekko): Amgen/AstraZeneca
TEZSPIRE (tezepelumab) was developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic and other types of airway inflammation associated with severe Asthma, including airway hyperresponsivenes. It is approved in the US, EU, Japan, and other countries for treating severe Asthma.
- CINQAIR (reslizumab): Teva Pharmaceutical
Reslizumab injection is a humanized interleukin-5 antagonist monoclonal antibody for add-on maintenance treatment of adult patients with severe Asthma and an eosinophilic phenotype developed by Teva Pharmaceuticals. CINQAIR is indicated for the add-on maintenance treatment of patients with severe Asthma aged 18 and older with an eosinophilic phenotype. It is approved in the US, EU, but not in Japan.
- FASENRA (benralizumab): AstraZeneca
FASENRA (benralizumab) is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death). FASENRA is AstraZeneca’s first respiratory biologic, approved as an add-on maintenance treatment in severe eosinophilic Asthma in the US, EU, Japan, and other countries, with further regulatory reviews ongoing.
Asthma Emerging Drugs
- GSK3511294 (Depemokimab): GlaxoSmithKline
GSK is developing GSK3511294 (depemokimab), a humanized anti-interleukin (IL)-5 monoclonal antibody, to treat severe eosinophilic Asthma. As a new biological entity, it is engineered to ensure high affinity and long-acting suppression of IL-5 functions. IL-5 is cytokines responsible for the proliferation, activation, and survival of eosinophils, thus making them a proven treatment target for severe Asthma patients with higher levels of eosinophils. Depemokimab, with an extended half-life and improved IL-5 affinity compared to other approved therapies, is the first biologic to be administered subcutaneously once every 26 weeks.
- PT010: AstraZeneca
PT010, being developed by AstraZeneca, is a fixed-dose combination of micronized budesonide, an inhaled corticosteroid (ICS), micronized glycopyrrolate (an anticholinergic), and micronized formoterol fumarate, a LABA, for oral inhalation administered via a pressurized metered-dose inhaler (pMDI) using Aerosphere delivery technology. AstraZeneca is conducting multiple Phase III trials to assess the safety and efficacy of PT010 in adults and adolescents with severe Asthma inadequately controlled with the standard of care.
Asthma Market Outlook
The goal of treatment is to minimize symptom burden (i.e., maintain normal activity levels while maintaining good symptom control) and reduce the possibility of adverse events such as fixed airflow limitation, exacerbations, and therapeutic side effects. Guidelines-based Asthma management emphasizes the severity of the condition and selecting the best medical treatment to manage symptoms and lower the likelihood of exacerbations.
Download DelveInsight’s Asthma Market report today and stay ahead in this rapidly evolving field. @ Asthma Clinical Trials
Scope of the Asthma Market Report
- Coverage- 7MM
- Asthma Companies- Cipla Ltd, Hamad Medical Corporation, Areteia Therapeutics, AstraZeneca, Amgen, GSK, Sanofi, TEVA Pharmaceutical, Regeneron Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, and others.
- Asthma Therapies- Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, Tezepelumab, GSK3511294 (Depemokimab), and others.
- Asthma Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Asthma Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement
Download the report to understand which factors are driving Asthma Market Trends @ Asthma Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Asthma Market Overview at a Glance
4 Methodology of Asthma Epidemiology and Market
5 Executive Summary of Asthma
6 Key Events
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Therapies
11 Emerging Therapies
12 Asthma: Market Analysis
13 KOL Views
14 SWOT Analysis
15 Unmet needs
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Asthma Treatment Market Size in the 7MM was ~USD 19,000 million in 2023, estimated DelveInsight